Compare Abbott Laboratories (ABT) vs Tesla, Inc. (TSLA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Tesla, Inc. — how do they compare? Abbott Laboratories trades at $95.16 (market cap $166.94B), while Tesla, Inc. trades at $393.4 (market cap $1.51T). The key difference: Tesla, Inc. is far larger — about 9× Abbott Laboratories's market cap, and Abbott Laboratories pays a 2.63% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| ABT | TSLA | |
|---|---|---|
Market Cap | $166.94B | $1.51T |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $489.88 |
52-Week Low | $82.57 | $295.88 |
Enterprise Value | $193.69B | $1.48T |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
Tesla (TSLA) is trading at $393.93, down 6.16% over the past 24 hours amid mixed technical signals and fundamental headwinds. The stock shows a neutral technical outlook with key support at $393 and resistance at $407, while valuation metrics remain elevated with a P/E ratio of 369.63. Recent earnings show inconsistent performance with a Q1 2026 beat but Q3 2025 miss, while revenue declined to $94.83B in 2025 from $97.7B in 2024.
Tesla faces near-term pressure from slowing auto demand and intense competition, though long-term growth potential exists in autonomous driving and energy businesses. The stock trades below the $429.91 consensus price target, offering potential upside if the company can execute on its AI and robotics initiatives. Key risks include execution challenges in new business lines and margin compression in the core EV market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
